|Table of Contents|

Value of blood calcium,PTHrP and PTH1R for the diagnosis of bone metastasis in NSCLC and the evaluation of radiotherapy efficacy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 01
Page:
45-50
Research Field:
Publishing date:

Info

Title:
Value of blood calcium,PTHrP and PTH1R for the diagnosis of bone metastasis in NSCLC and the evaluation of radiotherapy efficacy
Author(s):
WANG Su1; GAO Zhidi2; LU Tao3; LIU Peng1; ZHAO Kexin1
1.Qingdao Hiser Hospital Affiliated of Qingdao University（Qingdao Traditional Chinese Medicine Hospital） Oncology Department，Shandong Qingdao 266000,China；2.Qingdao Sixth People's Hospital Affiliated of Qingdao University，Shandong Qingdao 266033,China；3.Qingdao West Coast New Area Central Hospital，Shandong Qingdao 266555,China.
Keywords:
non-small cell lung cancer; bone metastasis; radiotherapy; blood calcium; PTHrP; PTH1R
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2025.01.008
Abstract:
Objective:To investigate the correlation of serum calcium,serum parathyroid hormone-related protein(PTHrP) and parathyroid hormone receptor 1(PTH1R) levels with bone metastasis in non-small cell lung cancer(NSCLC),and its value in the evaluation of radiotherapy efficacy.Methods:40 NSCLC patients with bone metastasis receiving local radiotherapy and treatment of zoledronic acid were investigated.40 patients with bone and 40 patients of non-bone metastases from NSCLC were selected.Patients with bone metastases received radiotherapy.Compare the levels of calcium,serum PTHrP,and PTH1R between the two groups before treatment.The correlation between the levels of three different blood substances,and the number of bone metastatic sites,course of disease in were analyzed in the bone metastasis group.The changes of the blood calcium,the serum PTHrP and PTH1R levels before and after therapy were also tested.Results:The levels of blood calcium,serum PTHrP and PTH1R were higher in bone metastasis patients than in non-bone metastasis patients(P＜0.05).Patients with more than 3 bone metastatic sites showed higher PTHrP levels compared with those with≤3 bone metastases(P＜0.05).A positive correlation was demonstrated between the course of disease and the PTHrP levels,where the longer course of disease was associated with the higher PTHrP levels(P＜0.01).The blood calcium and serum PTHrP levels were significantly reduced due to the radiotherapy(P＜0.001).Conclusion:Blood calcium,PTHrP,and PTH1R levels can used for the diagnosis of bone metastasis in NSCLC.The levels of blood calcium and serum PTHrP can be used as reference indicators for the evaluation of radiotherapy efficacy.

References:

[1] ZHANG J,CAI D,HONG S.Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study［J］.BMJ Open,2023,13(10):e069908.
[2] 董智,赵军,柳晨,等.肺癌骨转移诊疗专家共识(2019版)［J］.中国肺癌杂志,2019,22(04):187-207. DONG Z,ZHAO J,LIU C,et al.Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer(2019 Version) ［J］.Chin J Lung Cancer,2019,22(04):187-207.
[3] BINDELS B,MERCIER C,GAL R,et al.Stereotactic body and conventional radiotherapy for painful bone metastases:A systematic review and Meta-analysis［J］.JAMA Netw Open,2024,7(2):e2355409.
[4] ZHANG R,LI J,ASSAKER G,et al.Parathyroid hormone-related protein(PTHrP):An emerging target in cancer progression and metastasis［J］.Adv Exp Med Biol,2019,1164:161-178.
[5] GRUNBAUM A,KREMER R.Parathyroid hormone-related protein(PTHrP) and malignancy［J］.Vitam Horm,2022,120:133-177.
[6] ELAASSER B,ARAKIL N,MOHAMMAD KS.Bridging the gap in understanding bone metastasis:A multifaceted perspective［J］.Int J Mol Sci,2024,25(5):2846.
[7] 王劲松，魏家燕，彭敏.2023年美国癌症统计报告和全球最新癌症统计数据解读及启示［J］.实用肿瘤杂志,2023,38(7):523-527. WANG JS,WEI JY,PENG M.Interpretation and enlightenment of 2023 American cancer statistics report and the latest global cancer statistics ［J］.Journal of Practical Oncology,2023,38(7):523-527.
[8] 李纪宾,邹小农.全球癌症流行现状及环境致癌因素解析［J］.环境卫生学杂志,2023,13(11):795-801. LI JB,ZOU XN.Global cancer epidemic status and its environmental carcinogenic factors ［J］.Journal of Environmental Hygiene,2023,13(11):795-801.
[9] 洪方正,胡若愚,薛涛.肺癌骨转移机制的研究进展［J］.东南大学学报(医学版),2021,40(05):714-720. HONG FZ,HU RY,XUE T.Progress on investigating the mechanism of bone metastasis in lung cancer ［J］.J Southeast Univ(Med Sci Edi),2021,40(05):714-720.
[10] 滕小艳,魏丽荣,夏前林,等.肺癌骨转移分子机制及相关分子标志物临床意义的研究进展［J］.国际骨科学杂志,2020,41(03):138-142. TENG XY,WEI LR,XIA QL,et al.Progress on the molecular mechanism of bone metastasis and related molecular markers in lung cancer ［J］.Int J Orthop,2020,41(03):138-142.
[11] SHEEHAN MT,LI YH,DOI SA,et al.Evaluation of diagnostic workup and etiology of hypercalcemia of malignancy in a cohort of 167551 patients over 20 years［J］.J Endocr Soc,2021,5(11):bvab157.
[12] CHAI X,YINWANG E,WANG Z,et al.Predictive and prognostic biomarkers for lung cancer bone metastasis and their therapeutic value［J］.Front Oncol,2021,11:692788.
[13]吴昀喆，滕小艳，杜玉珍,等.肺癌骨转移机制相关血清学标志物的研究进展 ［J］.现代肿瘤医学,2024,32(13):2473-2479. WU Yunzhe,TENG Xiaoyan,DU Yuzhen,et al.Research progress on serological biomarkers related to mechanisms of lung cancer bone metastasis［J］.Modern Oncology,2024,32(13):2473-2479.
[14] MARTIN TJ,SIMS NA,SEEMAN E.Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor,PTH1R［J］.Endocr Rev,2021,42(4):383-406.
[15] CHIRGWIN JM,GUISE TA.Skeletal metastases:decreasing tumor burden by targeting the bone microenvironment［J］.J Cell Biochem,2007,102(6):1333-1342.
[16] 张双捷,王立峰.血清ALP、PINP、PTHrP对肺癌骨转移诊断的价值［J］.东南大学学报(医学版),2020,39(03):309-314. ZHANG SJ,WANG LF.Application of bone metabolism markers ALP，PINP and PTHrP in bone metastasis of lung cancer patients［J］.J Southeast Univ(Med Sci Edi),2020,39(03):309-314.
[17] 刘秀清,井鸿雁,赵玉双.肺癌骨转移血清中CaN和PTHrP测定的结果及意义分析［J］.中国实验诊断学,2019,23(08):1371-1373. LIU XQ,JING HY,ZHAO YS.Results and significance analysis of CaN and PTHrP measurements in lung cancer bone metastases［J］.Chin J Lab Diagn,2019,23(08):1371-1373.
[18]王华贝，庞海林，马丽，等.血清中CaN和PTHrP测定在肺癌骨转移诊断和疗效判定中的意义 ［J］.现代肿瘤医学，2012,20(05):945-947. WANG Huabei,PANG Hailin,MA Li,et al.Significance of serum CaN and PTHrP in lung cancer with bone metastases［J］.Modern Oncology,2012,20(05):945-947.
[19] LIU L,FAN Y,CHEN Z,et al.CaSR induces osteoclast differentiation and promotes bone metastasis in lung adenocarcinoma［J］.Front Oncol,2020,10:305.
[20] 武良权,潘巍,杨健.放疗联合唑来膦酸治疗非小细胞肺癌骨转移临床效果观察［J］.临床军医杂志,2021,49(01):83-84. WU LQ,PAN W,YANG J.Clinical effect of radiotherapy combined with zoledronic acid on bone metastasis in non-small cell lung cancer［J］.Clin J Med Offic,2021,49(01):83-84. ［21］ 曾少容,凌钦杰,曾维亮.唑来膦酸联合放射治疗对非小细胞肺癌骨转移患者癌痛的疗效观察［J］.临床肿瘤学杂志,2017,22(02):152-156. ZENG SR,LING QJ,ZENG WL.Effect observation of non-small cell lung cancer with osseous metastasis through zoledronic acid combined with radiotherapy［J］.Chinese Clinical Oncology,2017,22(02):152-156.
[22] GILLESPIE EF,YANG JC,MATHIS NJ,et al.Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases:A multicenter,randomized phase II clinical trial［J］.J Clin Oncol,2024,42(1):38-46.
[23] 罗青竹,丁广成,时昌立,等.立体定向放疗联合唑来膦酸治疗非小细胞肺癌脊柱转移疗效分析［J］.中国医药科学,2021,11(22):173-176. LUO QZ,DING GC,SHI CL,et al.Efficacy of stereotactic radiotherapy combined with zoledronic acid in the treatment of patients with spinal metastasis from non-small cell lung cancer ［J］.China Medicine and Pharmacy,2021,11(22):173-176.
[24] HU Y,REN H,YANG L,et al.Effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of COX-2 and VEGF in bone metastasis of lung cancer［J］.J BUON,2020,25(2):811-820.
[25] 李煜铭.唑来膦酸联合放疗治疗肺癌骨转移的疗效分析及骨代谢标记物变化［D］.青岛：山东大学,2019. LI YM.The rapeutic effect of zoledronic acid combined with radiotherapy on bone metastasis of lung cancer and changes of bone metabolic markers ［D］.Qingdao:Shandong University,2019.

Memo

Memo:
山东省中医药科技发展计划项目（编号：2019-0607）；山东省青岛市科技惠民示范引导专项（编号：20-3-4-49-NSH）
Last Update: 1900-01-01